Liquidia Corporation

LQDA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$68.39-0.09%

2026-09-17

Financials

Valuation Metrics

Liquidia Corporation's Market Cap is $6.08B. At end of 2025 it was $3.00B. Ranked #1216 of 3,121 in US market (top 39%), #405 of 1,463 on NASDAQ (top 28%), #68 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	$6.08B	US#1,216/3,121 Sec#68/266
Revenue	$451M	US#2,311/3,121 Sec#79/266
Net Income	$139M	US#1,487/3,121 Sec#48/266
Total Assets	$522M	US#2,753/3,121 Sec#161/266
Net Assets	$195M	US#2,692/3,121 Sec#195/266
Value
P/E	43.88x	US#1,862/3,121 Sec#52/266
P/B	31.17x	US#2,847/3,121 Sec#226/266
P/S	13.49x	US#2,765/3,121 Sec#124/266
EV/EBITDA	33.33x	US#2,263/3,121 Sec#65/266
FCF Yield	0.99%	US#2,184/3,121 Sec#76/266
Profitability
ROE	71.04%	US#66/3,121 Sec#6/266
ROA	26.56%	US#47/3,121 Sec#10/266
Op. Margin	37.39%	US#343/3,121 Sec#17/266
Revenue Growth	2233.65%	US#12/3,121 Sec#7/266
Financial Health
Debt Ratio	167.49%	US#1,615/3,121 Sec#192/266
Total Debt	$129M	US#2,372/3,121 Sec#107/266
FCF	$61M	US#1,919/3,121 Sec#67/266
Cash	$284M	US#1,462/3,121 Sec#83/266
Current Ratio	2.31x	US#1,078/3,121 Sec#213/266
Net Debt/EBITDA	-0.87x	US#305/3,121 Sec#21/266
Performance
1Y Return	173.56%	US#84/3,121 Sec#32/266
1M Return	-7.99%	US#2,199/3,121 Sec#166/266
From 52W High	-26.94%	US#1,890/3,121 Sec#145/266
1Y MDD	-35.66%	US#1,784/3,121 Sec#122/266
Trading
Volume	1,075,200 shares	US#1,330/3,121 Sec#143/266
Trading Value	$74M	US#1,006/3,121 Sec#71/266
Per Share
EPS	$1.56	US#1,487/3,121 Sec#39/266
BPS	$2.19	US#2,564/3,121 Sec#177/266